Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc.... Read More

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic... Read More

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE /... Read More

SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5"). The RSUs for New Employee 1 vest equally over three years, with one-third of the shares vesting each year starting... Read More

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of... Read More

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo... Read More

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the... Read More

Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 1:15pm... Read More

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 /... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's... Read More

FDA-approved Gelclair ® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference , which takes place September 9-11, 2024. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th... Read More

Company's Canalevia ® -CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month , a time devoted to raising awareness and... Read More

Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video interview of Lisa Conte, Jaguar's... Read More

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More

Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by... Read More

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in... Read More

Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday,... Read More

In 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide. 1 Click here to register for webcast. Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel... Read More

Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for... Read More

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected... Read More

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23 rd at 8:30 AM Eastern to provide updates on company's cancer... Read More

Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS... Read More

New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025 SAN FRANCISCO, CA /... Read More

JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that... Read More

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis In honor of World Rainforest Day (June... Read More

Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral... Read More

SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire. The RSUs for this new employee were granted as an inducement material to this new employee's acceptance of employment... Read More

SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire. The RSUs for this new employee were granted as an inducement material to this new employee's acceptance of... Read More

The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments and increasing royalties upon commercialization into the U.S. schizophrenia market, which is estimated to reach $8.06 billion by 2030 Jaguar to present May 30 at Lytham Partners... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool... Read More

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be... Read More

Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio... Read More

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to... Read More

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate... Read More

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German... Read More

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.... Read More

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with... Read More

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo... Read More

Jaguar planning to begin commercial launch of FDA-approved Gelclair ® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the... Read More

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair ® , a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine... Read More

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair ® , the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive... Read More

Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special... Read More

Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") has... Read More

Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today... Read More

Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial... Read More

Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide... Read More

Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement ("the Agreement") for Jaguar's novel plant-based, FDA-approved prescription drug... Read More

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the status of its listing with The Nasdaq Stock Market LLC ("Nasdaq"). "Jaguar requested a hearing to appeal a potential delisting of the Company's securities from Nasdaq, and I'm pleased to report that a hearing has been scheduled, " said Lisa Conte, Jaguar's president and... Read More

Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / February 15, 2024 / Jaguar Health, Inc.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi ® to Direct Relief , a Santa Barbara, California-based humanitarian aid organization. Active in all 50 states and more than 80 countries, with a mission to improve the health and lives of people affected by poverty or... Read More

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2024 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan... Read More

Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD, depression & anxiety SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences, Inc. (Magdalena), the... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey and participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February... Read More

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention and treatment of CTD Studies published in peer-reviewed journals and continuum of datapoints highlight the neglected and growing need for treatment of one of the most common and debilitating side effects of... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 4, 2024, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease - an ultrarare CDD - and short bowel syndrome (SBS) in the US, EU, and Middle East/North Africa regions, with results expected in 2024 SAN FRANCISCO, CA / ACCESSWIRE / January 4, 2024 / Napo Pharmaceuticals... Read More

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / December 11, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health,... Read More

To register for the webinar, click here SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Multinational Association of Supportive Care in Cancer (MASCC) webinar titled "GI Toxicities from Cancer Therapies - Prevention and Management," taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound... Read More

Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the... Read More

Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with results from the company's GCP (Good Clinical Practice) vendors supporting Napo's pivotal Phase 3 OnTarget trial . The trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult... Read More

Net revenue increased 5% in Q3 2023 versus Q2 2023 Top line results expected before Thanksgiving for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Tuesday, November 14th at 8:30 a.m. Eastern regarding Q3 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 14,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective November 7, 2023, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 9, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound challenges... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing... Read More

Click here to register for November 14 investor webcast Company plans to file its Earnings Report on November 14, 2023 on Form 10-Q for the quarter ended September 30, 2023 REMINDER: Jaguar to host virtual educational webinar on rare intestinal failure diseases with leading gastroenterologists and nutrition experts November 8, 2023 from 1:00 PM to 2:30 PM Eastern; Click here to register for webinar SAN FRANCISCO, CA /... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today issued a reminder that the company is hosting a virtual educational webinar with leading gastroenterologists and nutrition experts on intestinal failure associated with the rare diseases short bowel syndrome (SBS) and microvillus inclusion disease (MVID) on November 8, 2023 from 1:00 PM... Read More

Quadri Pharma will cover 50% of the costs of development activity up to a capped dollar contribution Jaguar to host virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts November 8 th from 1:00 PM to 2:30 PM EST; Click here to register for the webinar SAN FRANCISCO, CA / ACCESSWIRE / November 2, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc . (NASDAQ:JAGX) family... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2023 / Napo Pharmaceuticals (Napo), a... Read More

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64 th Emerging Growth Conference on November 1 st and 2 nd , 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.... Read More

Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health... Read More

Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from... Read More

Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. , the joint venture recently formed by... Read More

MVID, for which there are no approved drug treatments, is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for MVID, and the Company's Investigational New Drug application for... Read More

Mytesi ® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy Napo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conference SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual... Read More

Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that it is exhibiting at the Veterinary Cancer Society (VCS) Annual Conference , which takes place October 12-14, 2023... Read More

Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023... Read More

Lip-syncing and singing contest on social media features opportunity to duet with Grammy Award-winner Jenn Colella and encourages open dialogue about chronic and surprise diarrhea Visit the contest social channels @surprisediarrheacontest on TikTok and/or Instagram to enter contest All entries will support donation to nonprofit organization dedicated to supporting HIV long-term survivors; winners will receive prize money,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2023 / In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of... Read More

Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Authority SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that... Read More

Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More

New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE... Read More

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar intends to pursue a Tropical Disease Priority Review Voucher, under FDA's financial incentive program, to develop NP-300 for this indication SAN FRANCISCO, CA / ACCESSWIRE / September 12, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has... Read More

Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 Dr. Brunke to present at the October 30-November 2, 2023 World Orphan Drug Congress in Barcelona and the November 6-8, 2023 BIO-Europe ®... Read More

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing... Read More

Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 28, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's president, founder, and CEO, will present virtually at the Emerging Growth... Read More

Jaguar aims to leverage digital technologies including AI enhancement to help connect with investor communities SAN FRANCISCO, CA / ACCESSWIRE / August 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced it has engaged B2i Digital to execute an innovative digital investor engagement and... Read More

Company on track to report top line data in late October 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer... Read More

Jaguar Health family company Napo Pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2023 / Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral... Read More

Net revenue increased 36% in Q2 2023 versus Q1 2023 Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa... Read More

Click here to register for webcast Company plans to file its Earnings Report on August 14, 2023 on Form 10-Q for the quarter ended June 30, 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, August 14, 2023 at 8:30 a.m. Eastern Daylight Time to review second-quarter 2023 financials and provide corporate... Read More

Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in event of exposure to cholera due to bioterrorism or advancement of cholera into US territories due to global warming Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar to present August 10th at Emerging Growth Conference; Individual and... Read More

MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 8, 2023 / Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the... Read More

A significant proportion of patients undergoing cancer therapy experience diarrhea, which has the potential to cause dehydration and non-adherence to cancer treatment regimens Diarrhea was reported in 95% of neratinib-treated patients in randomized placebo-controlled trial SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") announced that the results of an... Read More

SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City at 1:30 p.m. EDT on Friday August 4, 2023. The Wall Street Wonders Investment Group is comprised of fund managers, money managers, retail brokers, family... Read More

Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the Company") today announced the activation by the U.S. Food and Drug Administration (FDA) of a physician-requested Investigational New Drug (IND) application to evaluate crofelemer for treatment of uncontrolled diarrhea... Read More

Activities support sustainable supply of Jaguar's botanical drug crofelemer, the active ingredient in the company's FDA-approved human drug Mytesi ® and FDA conditionally approved animal drug Canalevia ® -CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), in honor of World Nature Conservation Day, July 28 th , announced that Jaguar, together with its predecessor companies, and... Read More

Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA Crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar... Read More

Napo Medical Affairs Team Member, who is an HIV/Mytesi ® (Crofelemer) Patient, to Participate in Educational Panel SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2023 / Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals (Napo) today announced that it will be participating in Pineapple Healthcare's Butt Stuff Brunch with Doctor Carlton - an educational drag show and food event about sexual health featuring guest speaker... Read More

SAN FRANCISCO, CA / ACCESSWIRE / July 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2023 Annual Meeting of Stockholders held on July 7, 2023. Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A... Read More

MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2023 / Napo Pharmaceuticals Inc., a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and... Read More

SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) announced today that the Take C.H.A.R.G.E. ( C anine H ealth A nd R e G istry E xchange) has joined the Global Initiative for Veterinary Cancer Surveillance - an international network of veterinary cancer registries with a mission to: 1) promote international collaborations in animal cancer surveillance and research; 2) create a consensus on... Read More

Diarrhea is a highly neglected and unmet burden of cancer treatment in both people and dogs; A Jaguar-sponsored Gallup survey found that the incidence of U.S. dogs diagnosed with cancer in 2021 was approximately five times the incidence of cancer diagnosed in people SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is launching an... Read More

Reminder: Jaguar to Present at MedInvest Oncology Investor Conference Wednesday, June 21, 2023 at 6:00 p.m. EDT. Click Here to Register for Event Reminder: Ladenburg Thalmann to Host Virtual Discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care; Click Here to Register for Event SAN... Read More

Reminder: Ladenburg Thalmann to host virtual discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and leading patient advocates on impact of cancer therapy-related diarrhea on patients & importance of the patient voice in supportive care; Click here to register for event Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult... Read More

Click here to register for this virtual event taking place at 1:00 PM Eastern on June 22, 2023 Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / June 14, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that... Read More

First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, to Join International Consortium of Canine Cancer Registries SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar") today announced that it and the cosponsors of the Take C.H.A.R.G.E Canine Cancer Registry ( C anine H ealth A nd R e G istry E xchange), joined by their canine friends, leading veterinary oncologists, and... Read More

Dr. Radaelli appointed Interim Executive Director of Napo Therapeutics S.p.A., the corporation established by Jaguar Health in Italy in 2021 that focuses on expanding crofelemer access in Europe SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that on April 24, 2023, Massimo Radaelli, PhD, a European pharmaceutical industry leader and entrepreneur with more than 30... Read More

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has successfully over-enrolled its global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company's Scientific Advisory Board (SAB). "We are very pleased that Stacey has joined our SAB," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer. "Being a cancer... Read More

Announces Focus on Four Cancers Common to Children & Canines for Upcoming Capitol Hill Briefing, Commitment to Advancing Comparative Oncology According to the National Cancer Institute, Roughly 6 Million New Cancer Diagnoses are Made in Dogs Each Year in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) announced the one-year anniversary of the Take C.H.A.R.G.E. ( C anine H ealth A nd... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"), which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). These 499,171 shares... Read More

Jaguar Animal Health's Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet retailers in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 16, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and... Read More

Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the Phase 3 OnTarget trial Completed and core near-term milestones: Enrollment completed for Phase 3 OnTarget trial Submission of Investigational New Drug (IND)... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1... Read More

AI technology is expected to help make it faster and easier for Mytesi ® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved... Read More

Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the OnTarget trial SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2023 / Jaguar... Read More

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 2, 2023, the Company granted 100 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. All RSUs described above were... Read More

Proof-of-concept studies of crofelemer in patients with short bowel syndrome (SBS) with intestinal failure or congenital diarrheal disorders planned for 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Napo Therapeutics, the corporation Jaguar established in Italy in 2021 that focuses on expanding access to the Company's oral botanical drug... Read More

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia ® -CA1 over time Canalevia-CA1, Jaguar Health's FDA Conditionally Approved drug for chemotherapy-induced diarrhea (CID) in dogs, is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2023 / Jaguar... Read More

Enrollment expected to complete in mid-Q2 2023 As of March 24, 2023, as previously announced, the Company's cash position was approximately $15.3 million SAN FRANCISCO, CA / ACCESSWIRE / April 11, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in... Read More

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the Company's efforts to identify trading abnormalities in Jaguar's publicly traded Common Stock that could be markers of potential illegal naked short selling. "As we announced in February, Jaguar engaged Shareholder Intelligence Services, LLC ( ShareIntel ) to help uncover and... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA In December 2022, FDA increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000 SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the... Read More

Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021. As of March 24, 2023, the filing date of... Read More

Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board (SAB). "We are very pleased that Dr. Shanahan has... Read More

Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates. Participation Instructions for... Read More

The United Nations General Assembly's theme for the 2023 International Day of Forests is "Forests and Health" as Jaguar collaborates with communities in the Amazonia rainforest to ethically source the active ingredient in its FDA approved botanical drug SAN FRANCISCO, CA / ACCESSWIRE / March 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company, in advance of International... Read More

AI technology is expected to help make it faster and easier for Mytesi ® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved... Read More

Presentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has received orphan drug designation from the FDA and the European Medicines Agency for both SBS and a specific genetic abnormality resulting in a CDD condition SAN FRANCISO, CA / ACCESSWIRE / March 2, 2023 / Jaguar Health, Inc.... Read More

Crofelemer was previously granted Orphan Drug Designation by the FDA for short bowel syndrome SAN FRANCISCO, CA / ACCESSWIRE / February 28, 2023 / Jaguar Health (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD)... Read More

Company's IP estate includes approximately 200 patents issued and pending SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea... Read More

Addition of OnTarget trial sites in Europe, South America and Asia has significantly accelerated enrollment, which is expected to complete in Q2 2023 Adoption of premier digital health technology for data collection facilitates operational efficiency of this global trial SAN FRANCISCO, CA / ACCESSWIRE / February 21, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment... Read More

This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therapeutics Napo Therapeutics' mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications SAN... Read More

JAGX's securities continue to be listed on Nasdaq SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq's minimum bid price requirement. "We are very happy that Jaguar has regained compliance with... Read More

Tao Wang, SynWorld's General Manager and a long-term shareholder of restricted Jaguar stock, fully aligned on termination decision SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement (the "Canalevia... Read More

SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ( ShareIntel ), a leading compliance driven SAAS platform, to track market participants and analyze share ownership data in Jaguar's publicly traded Common Stock ("JAGX") on Nasdaq for SEC and FINRA market... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has entered into a consulting agreement with Andrew Mulberg, M.D. to enhance the company's regulatory expertise. Dr. Mulberg was formerly Deputy Director for six years in the Division of Gastroenterology and Inborn Errors Products at the U.S. Food and Drug Administration (FDA). "We are thrilled that Dr. Mulberg, the... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 19, 2023, the Company granted 7,500 restricted stock units (RSUs) to New Employee 1 and 7,500 RSUs to New Employee 2. (These RSU figures reflect grants made prior to the Jaguar reverse stock split that became effective January 23, 2023. Following this reverse stock split,... Read More

Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on short bowel syndrome Jaguar to take the lead on microvillus inclusion disease in the U.S., with the Company intending to submit an Investigational New Drug (IND) application to the FDA for this ultra-rare disease in 1H 2023 SAN FRANCISCO, CA / ACCESSWIRE / January 26, 2023 /... Read More

Milestone supports the expansion of manufacturing volume required for potential additional indications for crofelemer, including cancer therapy-related diarrhea Crofelemer API (active pharmaceutical ingredient) manufactured by Indena can now be used by Jaguar for development work Patient enrollment expected to complete in Q2 2023 for company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea... Read More

Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by... Read More